Table 1.
Administration of Anti-IL-23p19 and Anti-IL-12/23p40 Reduces EAE Clinical Disease
| Treatment regimen | Incidence | Median time to onset (days) | Disease burden over time (mean ± SEM) | Highest acute clinical sign (mean ± SEM) | No. of relapses (mean ± SEM) | Relapse severity (mean ± SEM) |
|---|---|---|---|---|---|---|
| Day −1 (start) | ||||||
| PBS | 13/13 (100%) | 22.5 | 1.66 ± 0.20 | 3.6 ± 0.3 | 0.7 ± 0.2 | 3.8 ± 0.1 |
| Rat IgG | 11/11 (100%) | 21.5 | 1.27 ± 0.20 | 3.8 ± 0.4 | 0.5 ± 0.2 | 3.5 ± 0.3 |
| Anti-IL-12/23p40 | 3/6 (50%)a,b | >69a,b | 0.18 ± 0.24a,b | 0.8 ± 0.5a,b | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Anti-IL-23p19 | 8/9 (89%) | 51.0a,b | 0.80 ± 0.24a | 2.8 ± 0.5 | 0.4 ± 0.2 | 3.3 ± 0.3 |
a
Significantly different from PBS at p < 0.05.
b
Significantly different from rat IgG at p < 0.05.